BioClinica, Inc. to Participate in Upcoming Industry Events and Demonstrate Global Technology–Enhanced Clinical Trial Management Capabilities

BioClinica, Inc. to Participate in Upcoming Industry Events and Demonstrate Global Technology–Enhanced Clinical Trial Management Capabilities

Company:Jim Dorsey, 267-757-3040orTrade Media:Beth Nesterode, 484-342-3600orInvestors:Michael Porter, 212-564-4700orFinancial Media:Bill Gordon, 212-564-4700

BioClinica, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and lead discussions at several upcoming industry conferences in October, November, and December. BioClinica experts will share industry trends and also demonstrate the company’s suite of eClinical Solutions and Imaging Core Lab Services. The conferences include:

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit .

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.